Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 18/20 | 0.60 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | PIR | O00625 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | STK16 | O75716 | 1/20 | 0.53 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | FES | P07332 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931060 | 0.90 | BRAF (0.49) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL413368 | 0.87 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL855654 | 0.87 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL9930989 | 0.86 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL9930598 | 0.86 | BRAF (0.55) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL12468027 | 0.86 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL412736 | 0.86 | CYP2C9 (0.60) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL16066858 | 0.85 | BRAF (0.57) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL9930589 | 0.85 | BRAF (0.54) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 | |
| SCHEMBL1868892 | 0.85 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19BRAFMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | claimed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | claimed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | claimed |
| EP-2170830-B1 | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS | PLEXXIKON INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | claimed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-06-13 | — | — | US | disclosed |
| EP-2493304-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-09-05 | — | — | EP | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2493865-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2470538-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP3A4 4658/4885CYP2C9 4746/4885CYP2C19 4579/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP3A4 3611/4885CYP2C9 2176/4885CYP2C19 2730/4885 |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP3A4 4658/4885CYP2C9 4746/4885CYP2C19 4579/4885 |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K11, MAP3K10 | CYP3A4 3607/4885CYP2C9 3648/4885CYP2C19 3521/4885 |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP3A4 2785/4885CYP2C9 2926/4885CYP2C19 2795/4885 |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP3A4 2785/4885CYP2C9 2926/4885CYP2C19 2795/4885 |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | CYP3A4 4658/4885CYP2C9 4746/4885CYP2C19 4579/4885 |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP3A4 4658/4885CYP2C9 4746/4885CYP2C19 4579/4885 |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP3A4 4658/4885CYP2C9 4746/4885CYP2C19 4579/4885 |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP3A4 4658/4885CYP2C9 4746/4885CYP2C19 4579/4885 |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP3A4 4658/4885CYP2C9 4746/4885CYP2C19 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.